Cardio Diagnostics (CDIO) director receives 2,854 stock options at $2.19
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cardio Diagnostics Holdings director Burton Paul Frederick received a grant of stock options, providing additional equity-based compensation. The award covers 2,854 options to buy Common Stock at an exercise price of $2.19 per share, expiring on June 30, 2036. Following this grant, Frederick holds 13,318 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Burton Paul Frederick
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 2,854 | $2.19 | $6K |
Holdings After Transaction:
Stock Options (Right to Buy) — 13,318 shares (Direct, null)
Footnotes (1)
Key Figures
Options granted: 2,854 options
Exercise price: $2.19 per share
Expiration date: June 30, 2036
+2 more
5 metrics
Options granted
2,854 options
Stock options granted on June 30, 2026
Exercise price
$2.19 per share
Conversion or exercise price for granted options
Expiration date
June 30, 2036
Expiration of granted stock options
Underlying shares
2,854 shares
Common Stock underlying newly granted options
Total options after grant
13,318 options
Direct derivative holdings following transaction
Key Terms
Stock Options (Right to Buy), Common Stock, Grant, award, or other acquisition
3 terms
Stock Options (Right to Buy) financial
"security_title: "Stock Options (Right to Buy)""
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
FAQ
What insider transaction did Cardio Diagnostics (CDIO) report for Burton Paul Frederick?
Cardio Diagnostics reported that director Burton Paul Frederick received a grant of 2,854 stock options. These derivative securities give him the right to buy Common Stock at $2.19 per share and are part of his equity-based compensation package.
What is the exercise price of the new Cardio Diagnostics (CDIO) stock options?
The newly granted stock options to Burton Paul Frederick have an exercise price of $2.19 per share. This price is the fixed cost at which he can purchase Cardio Diagnostics Common Stock before the options expire on June 30, 2036.
How many Cardio Diagnostics (CDIO) options does Burton Paul Frederick hold after this grant?
After this stock option grant, Burton Paul Frederick holds 13,318 stock options. This total reflects his direct derivative holdings in Cardio Diagnostics, including the 2,854 options granted on June 30, 2026 as compensation.
When do Burton Paul Frederick’s new Cardio Diagnostics (CDIO) options expire?
The 2,854 stock options granted to Burton Paul Frederick expire on June 30, 2036. He may choose to exercise them at $2.19 per share any time before that expiration date, subject to applicable plan and agreement terms.
Are Burton Paul Frederick’s new Cardio Diagnostics (CDIO) options direct or indirect holdings?
The Form 4 shows Burton Paul Frederick’s new stock options as direct holdings. The ownership code is listed as “D,” indicating he personally holds the derivative securities rather than through an intermediary entity or trust.